Opdivo’s approval for patients with resectable non-small cell lung cancer comes as the regulator recently raised concerns of ...
A phase 2/3 non-inferiority study compared de-escalation strategies to standard chemoradiation in patients with human ...
With a drug in advanced testing for two different indications that have spawned several blockbuster drugs, could Alumis be ...
June Squibb revisits her performance in 'Thelma' and chats about her role in Scarlett Johansson's directorial debut 'Eleanor ...
Hot on the tail of AstraZeneca’s Imfinzi, Bristol Myers Squibb’s PD-1/L1 inhibitor Opdivo has expanded its non-small cell lung cancer (NSCLC) net with an ...
The checkpoint inhibitor is now approved, based on CheckMate 77T findings, for neoadjuvant/adjuvant use in patients with ...
The cuts follow an ongoing wave of staff reductions at big drug companies. Pharma giants have terminated thousands of ...
Investor's Business Daily on MSN22h
Has Consumer Products Giant Bristol-Myers Squibb Kicked Into High Gear?A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?
The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...
With a recently acquired FDA nod for its Halozyme Therapeutics-partnered Vyvgat Hytrulo, argenx is looking to take Halozyme’s ...
Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...
By leveraging AI, drug developers are moving beyond incremental gains in efficiency and engaging previously undruggable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback